Education
About Us
Working with TipRanks
Follow Us
Gt Biopharma, Inc. (GTBP)
:GTBP
GTBP Stock Chart & Stats
$0.73
-$0.23(-8.01%)
At close: 4:00 PM EST
$0.73
-$0.23(-8.01%)
Day’s Range― - ―
52-Week Range$0.54 - $4.10
Previous CloseN/A
Volume15.05K
Average Volume (3M)1.19M
Market Cap
$7.02M
Enterprise Value-$308.77K
Total Cash (Recent Filing)$2.62M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Apr 01, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding10,636,135
10 Day Avg. Volume1,061,809
30 Day Avg. Volume1,185,831
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-3.46
Price to Sales (P/S)0.00
P/FCF Ratio-0.45
Enterprise Value/Market Cap-0.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.03
Forecast
1Y Price Target
$8.00Price Target Upside995.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.31
Revenue Forecast (FY)N/A
GT Biopharma News
GTBP FAQ
What was Gt Biopharma, Inc.’s price range in the past 12 months?
Gt Biopharma, Inc. lowest stock price was $0.54 and its highest was $4.10 in the past 12 months.
What is Gt Biopharma, Inc.’s market cap?
Gt Biopharma, Inc.’s market cap is $7.02M.
When is Gt Biopharma, Inc.’s upcoming earnings report date?
Gt Biopharma, Inc.’s upcoming earnings report date is Apr 01, 2026 which is in 106 days.
How were Gt Biopharma, Inc.’s earnings last quarter?
Gt Biopharma, Inc. released its earnings results on Nov 04, 2025. The company reported -$0.83 earnings per share for the quarter, missing the consensus estimate of -$0.38 by -$0.45.
Is Gt Biopharma, Inc. overvalued?
According to Wall Street analysts Gt Biopharma, Inc.’s price is currently Undervalued.
Does Gt Biopharma, Inc. pay dividends?
Gt Biopharma, Inc. does not currently pay dividends.
What is Gt Biopharma, Inc.’s EPS estimate?
Gt Biopharma, Inc.’s EPS estimate is -0.22.
How many shares outstanding does Gt Biopharma, Inc. have?
Gt Biopharma, Inc. has 10,636,135 shares outstanding.
What happened to Gt Biopharma, Inc.’s price movement after its last earnings report?
Gt Biopharma, Inc. reported an EPS of -$0.83 in its last earnings report, missing expectations of -$0.38. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Gt Biopharma, Inc.?
Currently, no hedge funds are holding shares in GTBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Gt Biopharma, Inc.
GT Biopharma, Inc. (GTBP) is a clinical-stage biopharmaceutical company focused on developing innovative therapies based on its proprietary TriKE (Tri-specific Killer Engager) platform. Operating in the biotechnology and pharmaceuticals sector, the company is dedicated to the discovery and development of immuno-oncology products designed to harness and enhance the body's natural immune system to target and destroy cancer cells. GT Biopharma's core product candidates aim to address various hematologic malignancies and solid tumors, offering a novel approach to cancer treatment.
GTBP Stock 12 Month Forecast
Average Price Target
$8.00
▲(995.89% Upside)
Technical Analysis
Theriva Biologics
―
Revelation Biosciences
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
Azitra Inc
―
Ownership Overview
8.05%
Insiders
0.27% Mutual Funds
1.53% Other Institutional Investors
90.08% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---